Gynecology and Physiopathology of Human Reproduction, S. Orsola-Malpighi Hospital, Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy.
Pediatric Division, Department of Obstetrics, Gynecology and Pediatrics, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.
Eur J Endocrinol. 2019 Dec;181(6):711-718. doi: 10.1530/EJE-19-0383.
To assess bone health in adult women with complete androgen insensitivity syndrome (CAIS) and removed gonads compared with age-matched healthy controls. To evaluate the effects of transdermal oestradiol 2 mg or oral estradiol valerate 2 mg on bone, biochemical and clinical characteristics.
Cohort study.
Bone, body composition and anthropometric parameters were assessed in 32 adult CAIS and 32 healthy controls. In 28 cases, CAIS evaluations of metabolic, bone and body composition were performed also after a maximum of 6 years of therapy.
Lumbar, femoral and total body bone mineral density (BMD) were significantly lower in those with CAIS when compared with controls. The prevalence of vertebral osteoporosis and osteopenia was significantly higher in the CAIS group (P = 0.038, OR = 9.67, 95% CI: 1.13-82.83 and P = 0.012, OR= 3.85, 95% CI: 1.34-11.16, respectively). Prevalence of femoral osteopenia was significantly higher in the CAIS group (P = 0.0012, OR = 7.93, 95% CI: 2.26-27.9). During follow-up, lumbar BMD significantly increased suggesting a significant effect of treatment on BMD (P = 0.0016), while femoral and total body BMD did not show any significant change. Total body BMD values were positively associated to the duration and route of oestrogen administration and to serum estradiol levels. Transdermal administration of estrogens was associated with better total body BMD in comparison to oral administration.
Our results reinforce the importance of adequate hormonal treatment for women living with CAIS, suggesting a better effect from the transdermal route over the oral route.
评估完全雄激素不敏感综合征(CAIS)女性患者去势后与年龄匹配的健康对照组的骨健康状况。评估透皮雌二醇 2mg 或口服戊酸雌二醇 2mg 对骨骼、生化和临床特征的影响。
队列研究。
评估 32 例成年 CAIS 患者和 32 例健康对照者的骨、身体成分和人体测量参数。在 28 例病例中,还进行了最多 6 年治疗后 CAIS 的代谢、骨骼和身体成分评估。
与对照组相比,CAIS 患者的腰椎、股骨和全身骨密度(BMD)明显较低。CAIS 组的椎体骨质疏松症和骨量减少的患病率明显较高(P = 0.038,OR = 9.67,95%CI:1.13-82.83 和 P = 0.012,OR = 3.85,95%CI:1.34-11.16)。CAIS 组股骨骨量减少的患病率明显较高(P = 0.0012,OR = 7.93,95%CI:2.26-27.9)。随访期间,腰椎 BMD 显著增加,表明治疗对 BMD 有显著影响(P = 0.0016),而股骨和全身 BMD 没有任何显著变化。全身 BMD 值与雌激素给药的持续时间和途径以及血清雌二醇水平呈正相关。与口服给药相比,透皮雌激素给药与更好的全身 BMD 相关。
我们的结果强化了对患有 CAIS 的女性进行充分激素治疗的重要性,提示透皮途径比口服途径效果更好。